Literature DB >> 20419764

A model for continuous quality control incorporating sample-to-sample assessment of optical alignment, fluorescence sensitivity, and volumetric operation of flow cytometers.

Denise Lawrie1, Lindi M Coetzee, Deborah K Glencross.   

Abstract

BACKGROUND: Bead count rate (BCR) monitoring successfully identifies pipetting error during single platform CD4 enumeration. Despite rigorous prescribed quality control performed, preliminary data suggested that BCR outliers could also be attributed to occasional failure of flow cytometric volumetric operation. The aim of this report was to use counting beads in a model of continuous quality control (CQC) to monitor overall flow cytometric performance (laser alignment, fluorescence stability and volumetric operation).
METHODS: The proposed CQC model used FlowCheck and IMMUNOTROL blood controls daily. Extended monitoring of fluidics (FPV; beads and sheath only) and sample preparation (SPV; blood, IMMUNOPREP and beads) was done daily on five flow cytometers over five consecutive days prior to testing patient samples. Sample-to-sample CQC included monitoring BCR, selected time/fluorescence histograms (Time vs. Count; Time vs. Fluorescence and Forward Scatter vs. Fluorescence) and full peak coefficient of variation (FPCV) for 2000 samples tested.
RESULTS: Prescribed quality controls showed Half Peak CV values of <2% (FlowCheck) with Immunotrol within 0.5SD of the target means. Laser stability was confirmed (FPCV values <2%). However, fluidics (volumetric operation) fluctuated as indicated by a 3.2% BCR outlier rate of 2,000 samples tested (minus pipetting error) despite optimal fluidics performance verified at start-up (FPV CV < 3%).
CONCLUSIONS: Sustained laser stability was confirmed with Time vs. Fluorescence histograms, but Time vs. Count histograms were insufficient to detect intermittent volumetric failure. The proposed CQC model, incorporating BCR monitoring with time/fluorescence histograms and FPCV monitoring can identify all volumetric inconsistencies in real-time. 2010 Clinical Cytometry Society.

Entities:  

Mesh:

Year:  2010        PMID: 20419764     DOI: 10.1002/cyto.b.20520

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  6 in total

1.  Performance evaluation of the Pima™ point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa.

Authors:  Deborah K Glencross; Lindi M Coetzee; Mamsallah Faal; Martin Masango; Wendy S Stevens; Wd Francois Venter; Regina Osih
Journal:  J Int AIDS Soc       Date:  2012-01-30       Impact factor: 5.396

2.  Estimating implementation and operational costs of an integrated tiered CD4 service including laboratory and point of care testing in a remote health district in South Africa.

Authors:  Naseem Cassim; Lindi M Coetzee; Kathryn Schnippel; Deborah K Glencross
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

3.  Performance verification of the new fully automated Aquios flow cytometer PanLeucogate (PLG) platform for CD4-T-lymphocyte enumeration in South Africa.

Authors:  Lindi-Marie Coetzee; Deborah K Glencross
Journal:  PLoS One       Date:  2017-11-03       Impact factor: 3.240

4.  Evaluation of fixed-panel, multicolour ClearLLab 10C at an academic flow cytometry laboratory in Johannesburg, South Africa.

Authors:  Deborah K Glencross; Leanne Swart; Melanie Pretorius; Denise Lawrie
Journal:  Afr J Lab Med       Date:  2022-07-15

5.  An integrated tiered service delivery model (ITSDM) based on local CD4 testing demands can improve turn-around times and save costs whilst ensuring accessible and scalable CD4 services across a national programme.

Authors:  Deborah K Glencross; Lindi M Coetzee; Naseem Cassim
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

6.  Performance Evaluation of the Becton Dickinson FACSPresto™ Near-Patient CD4 Instrument in a Laboratory and Typical Field Clinic Setting in South Africa.

Authors:  Lindi-Marie Coetzee; Keshendree Moodley; Deborah Kim Glencross
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.